SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Baird Initiates Coverage On Mirum Pharmaceuticals with Outperform Rating, Announces Price Target of $30

Baird analyst Brian Skorney initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform rating and announces Price Target of $30.

Benzinga · -
Baird analyst Brian Skorney initiates coverage on Mirum Pharmaceuticals (NASDAQ: MIRM) with a Outperform rating and announces Price Target of $30.